Vision Loss Clinical Trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 69 clinical trials
A Phase III Randomized Double-Blind Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
The purpose of the study is to compare letermovir to valganciclovir in preventing CMV disease in patients who have received a kidney transplant and are considered to be at high-risk for CMV disease after their transplant. The main study intervention is taking letermovir (or placebo for letermovir) plus valanciclovir (or …
A Phase 3 Multicenter Randomized Double- Blind Placebo- Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
The research study is being conducted to test the safety and tolerability (i.e., possible side effects) of an investigational drug called AL001 and to find out what effects AL001 has on the body. This is for people who have a confirmed progranulin gene mutation that causes frontotemporal dementia (FTD). Study …
A Phase II Randomized Double-Blind Multicenter Multinational Placebo-Controlled Parallel-Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects with Intermittent Claudication (IC)
In this research study an investigational product called PLX-PAD will be tested to see if it helps claudication. PLX-PAD is made up of mesenchymal-like stromal cells (MSCs), which are similar to stem cells. These cells come from a human placenta (afterbirth) from chosen female donor volunteers. From animal experiments it …
A Phase 1/2 Randomized Double-Blind Placebo-Controlled Combined Single and Multiple Ascending Dose Study Evaluating the Safety Tolerability and Biological Activity of MRT5005 (COhCFTR mRNA/ICE LNP) Administered by Nebulization to Adult Subjects with Cystic Fibrosis
This research study is being done to study a new way to possibly treat cystic fibrosis lung disease. The investigational drug to be tested in the present study is known by its code name MRT5005. MRT5005 consists of very small particles containing messenger ribonucleic acid (mRNA), which has the genetic …
A Multicenter Randomized Double-blind Vehicle-controlled Phase 3 Efficacy and Safety Study of Patidegib Topical Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome
Subjects 18 years or older diagnosed with basal cell nevus syndrome (BCNS, also known as Gorlin syndrome). The main purpose of this study is to see if the study gel, which is applied to the face, reduces the number of new surgically eligible BCCs and learn more about the safety …
A DOUBLE BLIND RANDOMIZED VEHICLE CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOPICAL NALOXONE HYDROCHLORIDE LOTION 0.5% FOR THE RELIEF OF PRURITUS IN PATIENTS WITH THE MYCOSIS FUNGOIDES (MF) FORM OF CUTANEOUS T-CELL LYMPHOMA (CTCL
This application is a request to execute a reliance agreement with Chesapeake an external IRB This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF), which is a type …
A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding …
A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy
A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, …
Cardiovascular Inflammation Reduction Trial (CIRT): A randomized double-blind placebo controlled event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome
This is an event-driven, multi-center, randomized, double-blind, placebo-controlled trial to determine whether methotrexate reduces heart attacks, strokes, or death in people who have already had at least one heart attack and have type 2 diabetes or metabolic syndrome. Metabolic syndrome is defined as a combination of problems including a large …
Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)
Adults 65 and older are more likely to have significant injuries from minor things like falls. They can have problems regaining strength due to sarcopenia (loss of muscle tissue as part of natural aging process). Nicotinamide riboside/pterstilbene (Basis) is commercially available nutraceutical. This randomized, double blind placebo controlled trial will …
